88 related articles for article (PubMed ID: 32575050)
1. Good things come in threes (and sometimes fours): Update on renin-angiotensin-aldosterone system inhibitors and COVID-19.
Quinn KL; Fralick M; Zipursky JS; Stall NM
CMAJ; 2020 Jun; 192(22):E611. PubMed ID: 32575050
[No Abstract] [Full Text] [Related]
2. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
[No Abstract] [Full Text] [Related]
3. Renin-Angiotensin-Aldosterone System Inhibitors Impact on COVID-19 Mortality: What's Next for ACE2?
Patel AB; Verma A
Clin Infect Dis; 2020 Nov; 71(16):2129-2131. PubMed ID: 32442259
[No Abstract] [Full Text] [Related]
4. Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?
Bloch MJ
J Am Coll Cardiol; 2020 Jul; 76(3):277-279. PubMed ID: 32674791
[TBL] [Abstract][Full Text] [Related]
5. Letter to the Editor - Circulating plasma levels of angiotensin II and aldosterone in patients with coronavirus disease 2019 (COVID-19): A preliminary report.
Henry BM; Benoit S; Lippi G; Benoit J
Prog Cardiovasc Dis; 2020; 63(5):702-703. PubMed ID: 32659343
[No Abstract] [Full Text] [Related]
6. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
Guo X; Zhu Y; Hong Y
Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
[No Abstract] [Full Text] [Related]
7. Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19.
Williams B; Zhang Y
Lancet; 2020 May; 395(10238):1671-1673. PubMed ID: 32416786
[No Abstract] [Full Text] [Related]
8. What Kind of Evidence Is Needed to Dictate Practice Regarding Inhibitors of the Renin-Angiotensin System in COVID-19?
Elijovich F; Laffer CL
Hypertension; 2020 Sep; 76(3):665-669. PubMed ID: 32783759
[No Abstract] [Full Text] [Related]
9. 5 classes of antihypertensive drugs were not linked to positive COVID-19 test results or severe COVID-19.
Fekete T
Ann Intern Med; 2020 Sep; 173(6):JC35. PubMed ID: 32926815
[TBL] [Abstract][Full Text] [Related]
10. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.
Speth RC
Drug Dev Res; 2020 Sep; 81(6):643-646. PubMed ID: 32304146
[No Abstract] [Full Text] [Related]
11. The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor?
Sever P; Johnston SL
J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320926911. PubMed ID: 32403977
[No Abstract] [Full Text] [Related]
12. COVID-19, Renin-Angiotensin System, and Hematopoiesis.
Çiftçiler R; Haznedaroğlu İC
Turk J Haematol; 2020 Aug; 37(3):207-208. PubMed ID: 32394689
[No Abstract] [Full Text] [Related]
13. Heartbeat: interaction of renin-angiotensin-aldosterone blocking drugs with COVID-19 disease susceptibility and severity.
Otto CM
Heart; 2020 Oct; 106(19):1451-1453. PubMed ID: 32928982
[No Abstract] [Full Text] [Related]
14. [ACE2 and coronavirus - a question of balance and dynamics?].
Lundström A; Sandén P
Lakartidningen; 2020 Apr; 117():. PubMed ID: 32314329
[TBL] [Abstract][Full Text] [Related]
15. Is there enough evidence to discontinue the renin-angiotensin system inhibitors in patients with COVID-19?
Bobkova I; Kamyshova E; Rudenko T; Stavrovskaya E; Moiseev S
Med Hypotheses; 2020 Oct; 143():109888. PubMed ID: 32480248
[No Abstract] [Full Text] [Related]
16. RAAS Inhibitors and Risk of Covid-19.
Sriram K; Loomba R; Insel PA
N Engl J Med; 2020 Nov; 383(20):1991-1992. PubMed ID: 33108103
[No Abstract] [Full Text] [Related]
17. RAAS Inhibitors and Risk of Covid-19.
Angeli F; Verdecchia P; Reboldi G
N Engl J Med; 2020 Nov; 383(20):1990-1991. PubMed ID: 33108102
[No Abstract] [
